AZT PROTECT adds Customers and Increased Reseller Partnerships to Accelerate Global Adoption
Read MoreOperating Cash Flow for the Six Months Ended June 30, 2024 Increased 71%;
Operating Expenses for the Three Months Ended June 30, 2024 Decreased 17%;
Announced Listing of Non-Core Asset in Chino Valley for $16 Million;
Announced Share Repurchase Program for up to $1 Million
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million
Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA discussion; Jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase 3 results
Jaguar planning to begin commercial launch in October 2024 for Gelclair®, the company's third prescription product
Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure
REMINDER: Jaguar to host investor webcast Tuesday, August 13th at 8:30 a.m. Eastern regarding Q2 2024 financials and company updates; Click here to register for webcast
Read More
